Executive Summary: Musculoskeletal Costs: Back, Joint, and Spine Claims and the Compounding Problem Most Plans Ignore
LFP-09.07 — The Cost Drivers#
Musculoskeletal conditions affect more than half of U.S. working-age adults and cost the healthcare system an estimated $420 billion annually according to Evernorth. The Business Group on Health’s 2025 employer survey found cancer and MSK conditions the top two cost drivers for large employers, with three out of four employers placing MSK in their top two categories. UnitedHealthcare’s analysis of its book of business documented MSK costs to employers at $40.51 per member per month. For a 25-person plan with $300,000 in annual claims, that translates to $45,000 to $60,000 in annual MSK spending. No individual claim in that total draws attention. The aggregate is substantial and invisible.
The cost distribution is what separates MSK from every other driver in this series. Specialty drugs concentrate cost in a few members at very high per-member expense. Pregnancy concentrates cost in high-variance events. MSK distributes cost across many members in small, unreportable increments: a $1,500 MRI, a $400 orthopedic consultation, a $2,400 PT course, a $2,800 epidural injection. None triggers a high-cost claimant report. None breaches any stop loss review threshold. Across six employees with chronic low back pain, the cumulative annual total is $42,000, invisible in standard reporting and unnoticed at renewal.
The compounding trajectory from conservative treatment through interventional procedures to surgery is clinically documented and visible in claims data for any TPA tracking it. The typical chronic low back pain pathway accumulates $12,000 in pre-surgical claims over 12 to 24 months, then produces a lumbar fusion at $80,000 to $150,000. Knee osteoarthritis progresses similarly from imaging through injections to total knee replacement at $30,000 to $50,000. The surgical claim arrives looking like a discrete event; the claims data documented its approach for years. Sun Life’s 2025 high-cost claims analysis ranked orthopedics and MSK as the third leading cost driver, with $1.18 billion in total spending for the reporting period. Published research suggests 35 percent of all MSK surgeries are not evidence-based or necessary.
The stop loss architecture has no mechanism for this cost profile. A member generating $8,000 in MSK claims across a plan year is nowhere near a $75,000 specific attachment point. Six members generating a combined $48,000 are invisible at the individual level. The aggregate compresses the claims fund without triggering any protection layer. MSK is the cost category most precisely calibrated to avoid every alarm in the system.
Construction, landscaping, manufacturing, warehousing, and home health carry MSK prevalence 50 to 100 percent higher than sedentary work according to CDC National Health Interview Survey data. Level funded adoption is growing fastest in precisely these industries. Virtual PT programs from vendors including Hinge Health and Sword Health, surgical second opinion programs, and facility steering to ambulatory surgery centers producing savings of $10,000 to $40,000 per orthopedic case each require TPA-level claims analytics to identify candidates before the surgical trajectory becomes irreversible.